JP2023535576A5 - - Google Patents

Info

Publication number
JP2023535576A5
JP2023535576A5 JP2023504517A JP2023504517A JP2023535576A5 JP 2023535576 A5 JP2023535576 A5 JP 2023535576A5 JP 2023504517 A JP2023504517 A JP 2023504517A JP 2023504517 A JP2023504517 A JP 2023504517A JP 2023535576 A5 JP2023535576 A5 JP 2023535576A5
Authority
JP
Japan
Prior art keywords
promoter
eef1a2
polynucleotide sequence
functional variant
pagh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/070455 external-priority patent/WO2022018171A1/en
Publication of JP2023535576A publication Critical patent/JP2023535576A/ja
Publication of JP2023535576A5 publication Critical patent/JP2023535576A5/ja
Pending legal-status Critical Current

Links

JP2023504517A 2020-07-23 2021-07-21 eEF1A2の遺伝子治療ベクターおよびその使用 Pending JP2023535576A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055775P 2020-07-23 2020-07-23
US63/055,775 2020-07-23
PCT/EP2021/070455 WO2022018171A1 (en) 2020-07-23 2021-07-21 GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2023535576A JP2023535576A (ja) 2023-08-18
JP2023535576A5 true JP2023535576A5 (cg-RX-API-DMAC7.html) 2024-07-30

Family

ID=71786970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504517A Pending JP2023535576A (ja) 2020-07-23 2021-07-21 eEF1A2の遺伝子治療ベクターおよびその使用

Country Status (10)

Country Link
US (1) US20230330265A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185332A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535576A (cg-RX-API-DMAC7.html)
KR (1) KR20230039669A (cg-RX-API-DMAC7.html)
CN (1) CN116171325A (cg-RX-API-DMAC7.html)
AU (1) AU2021312320A1 (cg-RX-API-DMAC7.html)
CA (1) CA3186700A1 (cg-RX-API-DMAC7.html)
IL (1) IL299955A (cg-RX-API-DMAC7.html)
MX (1) MX2023000995A (cg-RX-API-DMAC7.html)
WO (2) WO2022017630A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102673203B1 (ko) 2016-04-20 2024-06-10 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. Pklr의 유전자 발현 증강을 위한 조성물 및 방법
AU2018352583B2 (en) 2017-10-16 2025-04-17 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency
US12539316B2 (en) 2018-04-11 2026-02-03 Spacecraft Seven, Llc Compositions and methods for stem cell transplant
IL278213B2 (en) 2018-04-27 2026-04-01 Rocket Pharmaceuticals Ltd A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
IL280465B2 (en) 2018-07-30 2025-03-01 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Methods for gene modification of hematopoietic cells
WO2022032226A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
WO2026006785A2 (en) * 2024-06-28 2026-01-02 Adverum Biotechnologies, Inc. Melanopsin variants for vision restoration
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501686A (ja) 1994-04-13 1998-02-17 ザ ロックフェラー ユニヴァーシティ 神経系の細胞へのdnaのaav仲介送達
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US7122350B2 (en) * 2003-12-12 2006-10-17 Zymogenetics, Inc. Methods for enhancing expression of recombinant proteins
CA2693712C (en) 2007-07-14 2018-05-29 The University Of Iowa Research Foundation Methods and compositions for treating brain diseases
CA2793692A1 (en) 2010-04-02 2011-10-06 Ceregene, Inc. Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
EP3285788B1 (en) * 2015-04-23 2024-12-18 University of Massachusetts Modulation of aav vector transgene expression
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
EP3820537A4 (en) * 2018-07-12 2022-04-13 Spacecraft Seven, LLC GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE
IL283452B2 (en) * 2018-11-26 2026-04-01 Univ Barcelona Autonoma FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY

Similar Documents

Publication Publication Date Title
CN106488984B (zh) 一种治疗周围神经病变以及运动神经元疾病的方法
JP2023088902A5 (cg-RX-API-DMAC7.html)
JP2025179046A5 (cg-RX-API-DMAC7.html)
JP2022500066A5 (cg-RX-API-DMAC7.html)
JP2022535749A5 (cg-RX-API-DMAC7.html)
JP2023536902A5 (cg-RX-API-DMAC7.html)
JP2022501060A5 (cg-RX-API-DMAC7.html)
JP2023524291A5 (cg-RX-API-DMAC7.html)
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
JP2021531752A5 (cg-RX-API-DMAC7.html)
JP2023535956A5 (cg-RX-API-DMAC7.html)
JP2021523718A5 (cg-RX-API-DMAC7.html)
JP2022523679A5 (cg-RX-API-DMAC7.html)
JP2022531861A5 (cg-RX-API-DMAC7.html)
JP2021533805A5 (cg-RX-API-DMAC7.html)
JP2023534037A5 (cg-RX-API-DMAC7.html)
JP2024546103A5 (cg-RX-API-DMAC7.html)
JP2024539123A5 (cg-RX-API-DMAC7.html)
JP2024504611A5 (cg-RX-API-DMAC7.html)
WO2021081280A1 (en) Adeno-associated virus vectors based gene therapy for hereditary angioedema
JP2024528540A5 (cg-RX-API-DMAC7.html)
JP2022536338A5 (cg-RX-API-DMAC7.html)
JP2024545186A5 (cg-RX-API-DMAC7.html)
US20220233655A1 (en) Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme
JP2022525848A5 (cg-RX-API-DMAC7.html)